Tag: Objective

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

BRATISLAVA, Slovakia, July 02, 2025 (GLOBE NEWSWIRE) -- ESET Research has released a white paper about Gamaredon’s updated cyberespionage toolset, new stealth-focused techniques, and aggressive spearphishing operations observed across the previous year. Gamaredon, attributed by the Security Service of Ukraine (SSU) to the 18th Center of Information Security of Russia’s Federal Security Service (FSB), has targeted Ukrainian governmental institutions since at least 2013. In 2024, Gamaredon exclusively attacked Ukrainian institutions. ESET’s latest research shows that the group remains highly active, consistently targeting Ukraine, but has notably adapted its tactics and tools. The group’s objective is cyberespionage aligned with Russian geopolitical interests. Last year, the group significantly increased the scale and frequency of spearphishing campaigns, employing new delivery methods, and one attack payload was used solely to spread Russian propaganda.

HOUSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of June 30, 2025.

Press release – Paris, July 1^st, 2025, at 7:00 P.M. CEST

FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.